Literature DB >> 10690863

Relationship between serum inhibin A and B and ovarian follicle development after a daily fixed dose administration of recombinant follicle-stimulating hormone.

T Eldar-Geva1, D M Robertson, N Cahir, N Groome, M P Gabbe, V Maclachlan, D L Healy.   

Abstract

The aim of this study was to investigate the relationship of serum inhibin A and inhibin B to ovarian follicular development in women undergoing pituitary down-regulation and ovarian stimulation with a fixed daily dose of recombinant human FSH in an in vitro fertilization program. Thirty-eight patients were treated randomly with either 100 or 200 IU/day recombinant human FSH (Puregon) for a period of 9-14 days. Serum FSH, inhibin A, inhibin B, 17beta-estradiol, and follicular size and number were determined before FSH treatment and every second day from days 4-6 throughout FSH treatment. Serum FSH increased in a dose-related manner to reach a maximum by days 4-6 and remained unchanged over the duration of treatment. Serum inhibin A and 17beta-estradiol also increased with increasing FSH dose and continued to rise throughout the FSH treatment period. By contrast, serum inhibin B was increased by days 4-6 at both doses of FSH to reach a maximum by days 7-8, remaining unchanged thereafter. Serum inhibin B and, to a lesser extent, inhibin A correlated significantly with the number of oocytes retrieved even when assessed early (days 4-6) in the treatment period (inhibin B vs. number of oocytes: r = 0.89; P < 0.001; inhibin A vs. number of oocytes: r = 0.61; P < 0.05). Serum inhibin A, inhibin B, and 17beta-estradiol were weakly correlated with the number of follicles less than 11 mm when assessed on a daily basis; stronger correlations were observed with the greater than 11-mm follicles during the late stages of treatment. It is concluded that serum inhibin B levels determined during the early stages (e.g. days 4-6) of fixed dose FSH treatment provide an early indicator of the number of recruited follicles that are destined to form mature oocytes. In this context, serum inhibin B may be of predictive value in monitoring ovarian hyperstimulation treatment for in vitro fertilization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690863     DOI: 10.1210/jcem.85.2.6383

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing gnRH agonist versus antagonist protocols for ovarian hyperstimulation.

Authors:  Barbara Sonntag; Ludwig Kiesel; Eberhard Nieschlag; Hermann M Behre
Journal:  J Assist Reprod Genet       Date:  2004-07       Impact factor: 3.412

2.  Comparison of inhibin B and estradiol responses to intravenous FSH in women with polycystic ovary syndrome and normal women.

Authors:  Marcus A Rosencrantz; Deborah S Wachs; Mickey S Coffler; Pamela J Malcom; Michael Donohue; R Jeffrey Chang
Journal:  Hum Reprod       Date:  2009-10-22       Impact factor: 6.918

3.  Inhibin B predicts oocyte number and the ratio IGF-I/IGFBP-1 may indicate oocyte quality during ovarian hyperstimulation for in vitro fertilization.

Authors:  Gabriel Fried; Katarina Remaeus; Jonas Harlin; Elisabeth Krog; György Csemiczky; Arthur Aanesen; Michael Tally
Journal:  J Assist Reprod Genet       Date:  2003-05       Impact factor: 3.412

4.  Inhibin A-A Promising Predictive Parameter for Determination of Final Oocyte Maturation in Ovarian Stimulation for IVF/ICSI.

Authors:  Barbara Lawrenz; Leyla Depret Bixio; Carol Coughlan; Claus Yding Andersen; Laura Melado; Bhanu Kalra; Gopal Savjani; Human M Fatemi; Ajay Kumar
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-15       Impact factor: 5.555

5.  Expression and activity of Rac1 is negatively affected in the dehydroepiandrosterone induced polycystic ovary of mouse.

Authors:  Vineet Kumar Maurya; Chadchan Sangappa; Vijay Kumar; Sahil Mahfooz; Archana Singh; Singh Rajender; Rajesh Kumar Jha
Journal:  J Ovarian Res       Date:  2014-03-14       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.